AIM: To investigate the expressions of ornithine decarboxylase (ODC), MMP-2, and Erk, and their relationship in human colon tumors. METHODS: ODC activity, MMP-2 expression, and mitogen-activated protein (MAP) kinase activity (Erk phosphorylation) were determined in 58 surgically removed human colon tumors and their adjacent normal tissues, using [1-14C]-ornithine as a substrate, ELISA assay, and Western blotting, respectively. RESULTS: ODC activity, MMP-2 expression, and Erk phosphorylation were significantly elevated in colon tumors, compared to those in adjacent normal tissues. A significant correlation was observed between ODC activities and MMP-2 levels. CONCLUSION: This is the first report showing a significant correlation between ODC activities and MMP-2 levels in human colon tumors. As MMP-2 is involved in cancer invasion and metastasis, and colon cancer overexpresses ODC, suppression of ODC expression may be a rational approach to treat colon cancer which overexpresses ODC.
AIM: To investigate the expressions of ornithine decarboxylase (ODC), MMP-2, and Erk, and their relationship in humancolon tumors. METHODS:ODC activity, MMP-2 expression, and mitogen-activated protein (MAP) kinase activity (Erk phosphorylation) were determined in 58 surgically removed humancolon tumors and their adjacent normal tissues, using [1-14C]-ornithine as a substrate, ELISA assay, and Western blotting, respectively. RESULTS:ODC activity, MMP-2 expression, and Erk phosphorylation were significantly elevated in colon tumors, compared to those in adjacent normal tissues. A significant correlation was observed between ODC activities and MMP-2 levels. CONCLUSION: This is the first report showing a significant correlation between ODC activities and MMP-2 levels in humancolon tumors. As MMP-2 is involved in cancer invasion and metastasis, and colon cancer overexpresses ODC, suppression of ODC expression may be a rational approach to treat colon cancer which overexpresses ODC.
Authors: S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn Journal: Science Date: 1994-08-12 Impact factor: 47.728
Authors: H Li; H A Schut; P Conran; P M Kramer; R A Lubet; V E Steele; E E Hawk; G J Kelloff; M A Pereira Journal: Carcinogenesis Date: 1999-03 Impact factor: 4.944
Authors: S Wojtowicz-Praga; J Low; J Marshall; E Ness; R Dickson; J Barter; M Sale; P McCann; J Moore; A Cole; M J Hawkins Journal: Invest New Drugs Date: 1996 Impact factor: 3.850
Authors: R Hoshino; Y Chatani; T Yamori; T Tsuruo; H Oka; O Yoshida; Y Shimada; S Ari-i; H Wada; J Fujimoto; M Kohno Journal: Oncogene Date: 1999-01-21 Impact factor: 9.867
Authors: R R Love; R Jacoby; M A Newton; K D Tutsch; K Simon; M Pomplun; A K Verma Journal: Cancer Epidemiol Biomarkers Prev Date: 1998-11 Impact factor: 4.254
Authors: Jen Jen Yeh; Elizabeth D Routh; Tara Rubinas; Janie Peacock; Timothy D Martin; Xiang Jun Shen; Robert S Sandler; Hong Jin Kim; Temitope O Keku; Channing J Der Journal: Mol Cancer Ther Date: 2009-04 Impact factor: 6.261